Andelyn Biosciences Secures Independent Certification for Gene Therapy Manufacturing Systems

New updates have been reported about Andelyn Biosciences.

Andelyn Biosciences has obtained full certification under Dark Horse Consulting’s Initiative for Certification of Manufacturing Capabilities (ICMC), formally validating the CDMO’s readiness to manufacture advanced cell and gene therapies to global regulatory standards. The assessment, built around commercial GMP and biological drug product inspection guidance, examined Andelyn’s core systems, competencies, and infrastructure, positioning the company as a lower‑risk manufacturing partner for therapy sponsors seeking clinical and commercial support.

The ICMC review covered quality management, digital systems, facilities and equipment, materials handling, production operations, laboratory controls, and overall commercial readiness, directly reinforcing Andelyn’s ability to execute complex technology transfers and maintain robust GMP implementation. Leadership framed the certification as evidence of sustained investment in viral vector and plasmid manufacturing, process and analytical development, quality control, and its DIGITAL CDMO platform, which together underpin more than two decades of experience and over 500 GMP clinical batches. For biopharma clients, the independent verification is expected to reduce due‑diligence friction, support faster vendor selection, and enhance confidence that Andelyn can scale programs from early development through global trials and eventual commercialization, even though the certification does not replace product‑specific audits.